Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical use of salvianolic acid A

A technology of salvianolic acid and its use, which is applied in the new field of medical application, and can solve the problems such as the increase of cAMP content

Inactive Publication Date: 2011-10-12
无锡特吉特药物研究有限公司
View PDF2 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, salvianolic acid A can promote the increase of cAMP content in platelets and / or plasma, inhibit calcium ion concentration, inhibit adenylate activating enzyme, and inhibit platelet cytoplasmic calcium ion ([Ca 2+ ]i) The inhibitory effect of the concentration has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical use of salvianolic acid A
  • Medical use of salvianolic acid A
  • Medical use of salvianolic acid A

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0017] Experimental example 1: The effect of salvianolic acid A on platelet aggregation in vitro with different inducers

[0018] 1. Material

[0019] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0020] Acetylsalicylic acid (ASA), sigma company A5376

[0021] 3-isobutyl-1-methylxanthine (IBMX), sigma company I5879

[0022] Adenosine diphosphate (ADP), sigma company A2754

[0023] Thrombin (Thr), sigma company T4648

[0024] Arachidonic acid (AA), sigma company BMA001

[0025] Ethylenediamine diacetic acid disodium salt (EDTA.Na 2 ), Tianjin No. 1 Chemical Reagent Factory, batch number: 080616

[0026] Ethylene glycol diethyl ether diamine tetraacetic acid (EGTA), sigma company E4378

[0027] Hepes, sigma company H3375

[0028] Bovine serum albumin fifth component (BSA), Roche 738328

[0029] Sodium Citrate, Sinopharm Chemical Reagent Co., Ltd., batch number: F20071212

[0030] Anhydrous calcium chloride (CaCl 2 ), Sinopharm Chemical Reagent Co., Ltd., batch number: ...

experiment example 2

[0050] Experimental example 2: The effect of salvianolic acid A on the content of cAMP in platelets and the activities of phosphodiesterase and adenylate cyclase in platelets

[0051] 1. The effect of salvianolic acid A on cAMP content in platelets

[0052] 1.1 Material

[0053] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0054] 3-Isobutyl-1-methylxanthine (IBMX), sigma company, batch number: I5879, dissolved in physiological saline in a water bath at 100°C, with a concentration of 10mM.

[0055] Adenosine diphosphate (ADP), Sigma company, batch number: A2754, prepared with physiological saline to prepare a solution with a concentration of 300 μmol / l.

[0056] Ethylenediaminetetraacetic acid disodium salt (EDTA), Tianjin No. 1 Chemical Reagent Factory, batch number: 080616, prepared with deionized water.

[0057] Ethylene glycol diethyl ether diamine tetraacetic acid (EGTA), sigma company, batch number: E4378

[0058] Hepes, sigma company, batch number: H3375 ...

experiment example 3

[0104] Experimental Example 3: Determination of Salvianolic Acid A on Free [Ca2+]i in Platelets

[0105] 1. Material

[0106] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0107] Adenosine Diphosphate (ADP): sigma company A2754

[0108] Acetyl hydroxymethyl ester (Fura-2 / AM): product of sigma

[0109] TritonX-100, purchased from Huamei Bioengineering Company

[0110] Animals: SPF-grade SD rats, male, weighing 300-350g, purchased from the Laboratory Animal Center of Peking University Medical Department, certificate number: SCXK (Beijing) 2006-0008.

[0111] 2. Methods and results

[0112] Blood was taken from the abdominal aorta of the rat, and 3.8% sodium citrate (1:9) was used for anticoagulation to prepare PRP. Take PRP, add Fura-2 / AM with a final concentration of 2μmol / L, shake for 30min at 37°C in the dark. Ca-free 2+ Wash 2 times with Tyrode-Hepes solution to remove excess Fura-2 / AM from platelets, and finally suspend in Ca 2+ Tyrode-Hepes solution, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines and discloses the new use of salvianolic acid A, in particular the use of salvianolic acid A in the preparation of medicines for increasing cyclic adenosine monophosphate (CAMP) content in soterocyte and / or blood plasma, preparation of medicines for inhibiting activity of phosphodiesterase in soterocyte, preparation of medicines for promoting activity of adenylate activating enzyme and preparation of medicines for inhibiting calcium ion concentration in cytoplasm of soterocyte, in particular preparation of medicines for preventing or treating myocardial ischemia-reperfusion injury caused by thrombolysis, percutaneous coronary intervention, coronary artery bypass surgery and the like.

Description

Technical field [0001] The present invention relates to a new medicinal use of salvianolic acid A, and specifically refers to its use in the preparation of drugs for the treatment of cardiovascular and cerebrovascular diseases. Background technique [0002] cAMP is widely present in various cells and plays an important role in regulating cell function and metabolism. Pharmacological tests show that exogenous cAMP has the functions of relaxing smooth muscle, dilating blood vessels, improving liver function, promoting nerve regeneration, inhibiting cell division and transformation of abnormal cells in the outer layer of the skin, promoting the activity of respiratory chain oxidase, improving myocardial hypoxia, etc. . Elevating the content of cAMP can be used to treat the following conditions, including but not limited to: thromboembolic disease, peripheral vascular disease, artificial heart valve, congestive heart failure, coronary artery bypass surgery, viral myocarditis, arrhyt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P9/00A61P9/10A61P7/02A61P9/04A61P9/06A61P5/16A61P37/08A61P37/02A61P25/24A61P1/16A61P11/06A61P9/12A61P11/00A61P3/10
Inventor 刘珂范华英刘军锋何克江杨明艳
Owner 无锡特吉特药物研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com